Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Trial Profile

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Therapeutic Use
  • Acronyms SIGNATURE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Nov 2015 Results of sub-group analysis (n=11) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
    • 05 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top